Multiple Ascending Dose Study of AR882 in Healthy Adult Male Volunteers
NCT ID: NCT04314986
Last Updated: 2020-11-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
30 participants
INTERVENTIONAL
2019-06-28
2019-09-18
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SEQUENTIAL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
AR882 (Dose A)
Cohort 1: AR882 or placebo
AR882 or matching placebo administered once daily for 10 days
AR882 (Dose B)
Cohort 2: AR882 or placebo
AR882 or matching placebo administered once daily for 10 days.
AR882 (Dose C)
Cohort 3: AR882 or placebo
AR882 or matching placebo administered once daily for 10 days
AR882 (Dose D)
Cohort 4: AR882 or placebo
AR882 or matching placebo administered once daily for 10 days
Placebo
Cohort 1: AR882 or placebo
AR882 or matching placebo administered once daily for 10 days
Cohort 2: AR882 or placebo
AR882 or matching placebo administered once daily for 10 days.
Cohort 3: AR882 or placebo
AR882 or matching placebo administered once daily for 10 days
Cohort 4: AR882 or placebo
AR882 or matching placebo administered once daily for 10 days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Cohort 1: AR882 or placebo
AR882 or matching placebo administered once daily for 10 days
Cohort 2: AR882 or placebo
AR882 or matching placebo administered once daily for 10 days.
Cohort 3: AR882 or placebo
AR882 or matching placebo administered once daily for 10 days
Cohort 4: AR882 or placebo
AR882 or matching placebo administered once daily for 10 days
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Body weight no less than 50 kg and body mass index (BMI) within the range of ≥18 and ≤33 kg/m2
* Must be free of any clinically significant disease that requires a physician's care and/or would interfere with study evaluations or procedures
Exclusion Criteria
* History of cardiac abnormalities
* History and/or presence of drug addiction or excessive use of alcohol
18 Years
55 Years
MALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Arthrosi Therapeutics
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Nucleus Network Pty, Ltd.
Melbourne, Victoria, Australia
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AR882-102
Identifier Type: -
Identifier Source: org_study_id